$9.15
0.030.32%
At close: -
Comments
Loading...
Astellas Pharma Analyst Ratings and Price Targets | OTC:ALPMY | Benzinga
Astellas Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Astellas Pharma Corp from these most-recent analyst ratings.
Analyst Ratings for Astellas Pharma
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Astellas Pharma (ALPMY) stock?
There is no price target for Astellas Pharma
What is the most recent analyst rating for Astellas Pharma (ALPMY)?
There is no analyst for Astellas Pharma
When was the last upgrade for Astellas Pharma (ALPMY)?
There is no last upgrade for Astellas Pharma
When was the last downgrade for Astellas Pharma (ALPMY)?
There is no last downgrade for Astellas Pharma.
When is the next analyst rating going to be posted or updated for Astellas Pharma (ALPMY)?
There is no next analyst rating for Astellas Pharma.
Is the Analyst Rating Astellas Pharma (ALPMY) correct?
There is no next analyst rating for Astellas Pharma.
Browse analyst ratings and price targets on all stocks.
